Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Mature
Primary summary from verified readiness
- Confidence
- 65% · fresh
- Computed at
- 2026-09-22T00:12:02.209038+00:00
- Claimed
- 100
- Reported
- 99
- Verified
- 89
- Gap
- +11
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-09-22
Adopt with guardrails
- Why
- FDA approval (2026-08-28) rests on Phase 3 data (76.9% versus 32.9% placebo clinical response, all four secondary endpoints met), with Takeda commercialization support. Hematocrit control is a surrogate: clot, stroke and mortality benefit remains unproven, response is not universal, and payer access friction warrants monitoring.
- Next
- Track post-launch real-world hematocrit-control durability, long-term clot/stroke/mortality outcome data, and payer access friction over the next 2-4 quarters before treating rusfertide as a default standard-of-care add-on
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 4
- Tier 1
- 1
- Tier 2
- 2
- Tier 3
- 1
- Supports
- 3
- Contradicts
- 1
- Context
- 0
- Latest observed
- 2026-09-01
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-09-21 Reading moved from mature to mature.